BioCatalyst

ARDX — ARDELYX, INC. catalysts

2 verified catalyst event(s) for ARDELYX, INC. (ticker ARDX). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-07-01 — 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-07 (month)
in 9d
ESTIMATED
 READOUT
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
Phase 2 · Irritable Bowel Syndrome With Constipation (IBS-C)
 ARDX ARDELYX, INC. Tenapanor ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-09-01
in 2mo
ESTIMATED
 READOUT
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pedia
Phase 3 · Irritable Bowel Syndrome With Constipation (IBS-C)
 ARDX ARDELYX, INC. Tenapanor 50 MG, Tenapanor 25 mg bid ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.